Royalty Pharma plc

RPRX

GB00BMVP7Y09

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
28 ^USD	-0.39%		-0.57%	-0.32%

Apr. 17	Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	MT
Apr. 17	Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	CI

Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 15, 2024 at 07:34 am EST

Royalty Pharma plc reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 596 million compared to USD 566 million a year ago. Net income was USD 494 million compared to net loss of USD 456 million a year ago.

Latest news about Royalty Pharma plc

Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	Apr. 17	MT
Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	Apr. 17	CI
Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	Apr. 09	MT
Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM	Mar. 05
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	Feb. 20	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating	Feb. 20	MT
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023.	Feb. 15	CI
Royalty Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Royalty Pharma Swings to Q4 Net Income, Revenue Increases	Feb. 15	MT
Transcript : Royalty Pharma plc, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q4 Revenue $596M, vs. Street Est of $674.5M	Feb. 15	MT
Novartis wants to swallow Morphosys - access to beacon of hope	Feb. 06	DP
Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG for ?2.7 billion.	Feb. 04	CI
Royalty Pharma Raises Quarterly Dividend by 5% to $0.21 per Class A Share, Payable March 15 to Shareholders of Record on Feb. 16	Jan. 19	MT
Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024	Jan. 19	CI
Transcript : Royalty Pharma plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM	Jan. 09
Royalty Pharma Insider Sold Shares Worth $13,222,862, According to a Recent SEC Filing	Jan. 04	MT
Royalty Pharma plc and Royalty Pharma Holdings Ltd Enters into Amendment No. 3 to the Amended and Restated Revolving Credit Agreement	Dec. 27	CI
PureTech Health Provides Updates on Programs, Reports Strong Financial Position	Dec. 20	MT
Morphosys raises more than 100 million euros with capital increase	Dec. 14	DP
The only way is up…	Dec. 12
Morgan Stanley Cuts Price Target on Royalty Pharma to $46 From $57, Keeps Overweight Rating	Dec. 12	MT
ANALYST RECOMMENDATIONS : Adobe, Amgen, Blackrock, IBM, Ulta Beauty...	Dec. 12
Transcript : Royalty Pharma plc Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 03:00 PM	Nov. 28

Chart Royalty Pharma plc

Duration

Period

More charts

Company Profile

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertexâs Trikafta, GSKâs Trelegy, Rocheâs Evrysdi, Johnson & Johnsonâs Tremfya, Biogenâs Tysabri and Spinraza, AbbVie and Johnson & Johnsonâs Imbruvica, Astellas and Pfizerâs Xtandi, Novartisâ Promacta, Pfizerâs Nurtec ODT and Gileadâs Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Royalty Pharma plc

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28 USD

Average target price

45.4 USD

Spread / Average Target

+62.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROYALTY PHARMA PLC	-0.32%	12.63B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals